×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CHRS – coherus biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CHRS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/18
08:38 am
chrs
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 [Yahoo! Finance]
Medium
Report
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 [Yahoo! Finance]
12/18
08:30 am
chrs
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Medium
Report
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
12/18
08:14 am
chrs
Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases [Yahoo! Finance]
Medium
Report
Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases [Yahoo! Finance]
12/5
08:28 am
chrs
Coherus BioSciences, Inc. (NASDAQ: CHRS) had its price target raised by analysts at Robert W. Baird from $4.00 to $6.00. They now have an "outperform" rating on the stock.
High
Report
Coherus BioSciences, Inc. (NASDAQ: CHRS) had its price target raised by analysts at Robert W. Baird from $4.00 to $6.00. They now have an "outperform" rating on the stock.
12/4
08:09 am
chrs
Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
12/3
07:42 am
chrs
Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth [Yahoo! Finance]
Medium
Report
Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth [Yahoo! Finance]
12/3
07:18 am
chrs
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. [Yahoo! Finance]
Low
Report
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2024
04:01 pm
CHRS
coherus biosciences, inc.
BEAT
Report
14.1%
coherus biosciences, inc.
5/9/2024
04:01 pm
CHRS
coherus biosciences, inc.
MISS
Report
-10.4%
coherus biosciences, inc.
3/13/2024
04:01 pm
CHRS
coherus biosciences, inc.
MISS
Report
-5.7%
coherus biosciences, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/17
04:44 pm
chrs
Form 4 Coherus BioSciences, For: Dec 13 Filed by: Reider Paul
Medium
Report
Form 4 Coherus BioSciences, For: Dec 13 Filed by: Reider Paul
12/4
04:29 pm
chrs
Form 8-K Coherus BioSciences, For: Nov 27
High
Report
Form 8-K Coherus BioSciences, For: Nov 27
12/4
04:28 pm
chrs
Form DEFA14A Coherus BioSciences,
High
Report
Form DEFA14A Coherus BioSciences,
12/4
06:01 am
chrs
Form DEFA14A Coherus BioSciences,
Medium
Report
Form DEFA14A Coherus BioSciences,
12/3
05:22 pm
chrs
Form DEFA14A Coherus BioSciences,
Neutral
Report
Form DEFA14A Coherus BioSciences,
12/3
07:14 am
chrs
Form DEFA14A Coherus BioSciences,
Medium
Report
Form DEFA14A Coherus BioSciences,
12/3
07:11 am
chrs
Form 8-K Coherus BioSciences, For: Dec 02
High
Report
Form 8-K Coherus BioSciences, For: Dec 02
11/13
04:31 pm
chrs
Form SC 13G Coherus BioSciences, Filed by: Rubric Capital Management LP
Medium
Report
Form SC 13G Coherus BioSciences, Filed by: Rubric Capital Management LP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/1
Q2/2019 6/30/2019 EPS 0.320 ZacksConsensus -0.080 ActVsEst 0.400 - Beat
17.6%
11/6 Form 8-K Coherus BioSciences, For: Nov 06 16.9%
1/13 Form 4 Coherus BioSciences, For: Jan 09 Filed by: HEALY JAMES 14.4%
2/27 Form 8-K Coherus BioSciences, For: Feb 27 13.8%
5/9 Form 8-K Coherus BioSciences, For: May 09 9.6%
3/24 Coherus Biosciences Inc (NASDAQ: CHRS) was upgraded by analysts at TheStreet from a "d+" rating to a "c-" rating. 9.4%
4/20 Coherus Biosciences: Worth The Risks [Seeking Alpha] 7.9%
8/21 Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in September 7.0%
3/1 Coherus Biosciences Inc (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $27.00 price target on the stock. 7.0%
3/20 Coherus BioSciences Announces New Employment Inducement Grants 6.5%
11/6 Form 8-K Coherus BioSciences, For: Nov 06 16.9%
1/13 Form 4 Coherus BioSciences, For: Jan 09 Filed by: HEALY JAMES 14.4%
2/27 Form 8-K Coherus BioSciences, For: Feb 27 13.8%
5/9 Form 8-K Coherus BioSciences, For: May 09 9.6%
3/24 Coherus Biosciences Inc (NASDAQ: CHRS) was upgraded by analysts at TheStreet from a "d+" rating to a "c-" rating. 9.4%
4/20 Coherus Biosciences: Worth The Risks [Seeking Alpha] 7.9%
8/21 Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in September 7.0%
3/1 Coherus Biosciences Inc (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $27.00 price target on the stock. 7.0%
3/20 Coherus BioSciences Announces New Employment Inducement Grants 6.5%
TOP News Decliners
7/8
Coherus BioSciences Announces Unaudited Second Quarter 2019 UDENYCA® Net Sales of $79 Million to $84 Million
-14.3%
5/7 Coherus Biosciences Inc (NASDAQ: CHRS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $28.00 price target on the stock. -7.9%
11/25 Form 4 Coherus BioSciences, For: Nov 21 Filed by: Lanfear Dennis M -7.8%
9/25 Form 4 Coherus BioSciences, For: Sep 23 Filed by: Viret Jean-Frederic -7.4%
4/14 Form 8-K Coherus BioSciences, For: Apr 13 -6.4%
5/24 Form 4 Coherus BioSciences, For: May 22 Filed by: HEALY JAMES -5.8%
10/22 Form 4 Coherus BioSciences, For: Oct 18 Filed by: Viret Jean-Frederic -5.5%
3/5 Coherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020 -5.0%
5/10 Coherus Biosciences Inc (NASDAQ: CHRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.2%
1/13 Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States -4.1%
5/7 Coherus Biosciences Inc (NASDAQ: CHRS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $28.00 price target on the stock. -7.9%
11/25 Form 4 Coherus BioSciences, For: Nov 21 Filed by: Lanfear Dennis M -7.8%
9/25 Form 4 Coherus BioSciences, For: Sep 23 Filed by: Viret Jean-Frederic -7.4%
4/14 Form 8-K Coherus BioSciences, For: Apr 13 -6.4%
5/24 Form 4 Coherus BioSciences, For: May 22 Filed by: HEALY JAMES -5.8%
10/22 Form 4 Coherus BioSciences, For: Oct 18 Filed by: Viret Jean-Frederic -5.5%
3/5 Coherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020 -5.0%
5/10 Coherus Biosciences Inc (NASDAQ: CHRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.2%
1/13 Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States -4.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: